PF-07976016-87

PF-07976016-87 is an investigational substance being developed by Pfizer Inc. for the treatment of obesity and overweight. It is a chemically synthesised substance that is given by mouth as a film-coated tablet.^[1] The product records in the European trial registry show no marketing authorisation for PF-07976016-87, meaning it is not yet an approved medicine.^[1]

What is PF-07976016-87?

PF-07976016-87 is a chemical substance of synthetic origin, developed as an oral medicine for the treatment of obesity and overweight.^[1] It is classified in the registry under nutritional and metabolic diseases, which includes conditions such as obesity, as well as otorhinolaryngologic diseases.^[1] The substance is currently investigational, with no marketing authorisation in the product records.^[1] In the registered trial, PF-07976016-87 was given as a film-coated tablet for oral use.^[1]

How does PF-07976016-87 work?

The registry records do not describe the mechanism of action of PF-07976016-87. The trial data show that the substance was studied in combination with liraglutide, a medicine used for weight management, but the specific way in which PF-07976016-87 acts in the body is not stated in the available sources.^[1]

Which conditions is PF-07976016-87 studied for?

• Obesity — a condition of excess body fat that can affect health; the trial enrolled adults with obesity.^[1]
• Overweight — a body weight above what is considered healthy; the trial also included participants with overweight.^[1]

How is PF-07976016-87 given?

PF-07976016-87 is given by mouth as a film-coated tablet.^[1] The exact dose levels used in the trial were not reported in the registry record.^[1] The trial also included liraglutide as a background treatment, given by subcutaneous injection, and a placebo for PF-07976016-87 given orally.^[1]

What do the clinical trials show?

The clinical research programme for PF-07976016-87 consists of one completed Phase 2 trial with 255 participants.^[1] The trial compared the effect of multiple dose levels of PF-07976016-87 versus placebo on body weight in participants with obesity, on a background of liraglutide.^[1] The primary measure was the percent change from baseline in body weight at Week 16.^[1] The trial is registered in the EU Clinical Trials Information System under the number 2024-513679-42-00.^[1]

What side effects are known?

The registry record for the completed Phase 2 trial does not report side effects for PF-07976016-87.^[1] No supplementary sources describing the safety profile of the substance were provided.